Stock Track | Zimmer Biomet Soars 5.32% Intraday on Q4 Earnings Beat and Strong Hips, Knees Device Demand

Stock Track

Feb 10

Zimmer Biomet's stock surged 5.32% during intraday trading on Tuesday, following the company's release of its fourth-quarter financial results.

The medical device maker reported quarterly adjusted earnings of $2.42 per share, beating analyst estimates of $2.40. Quarterly sales reached $2.244 billion, also surpassing expectations of $2.231 billion and marking a 10.9% increase year-over-year. The strong performance was driven by robust demand for the company's hips and knees devices, with both segments reporting sales growth.

Additionally, Zimmer Biomet announced that its board approved a new $1.5 billion stock repurchase authorization, providing further support to shareholder value. The company also issued its 2026 financial guidance, projecting adjusted earnings per share in the range of $8.30 to $8.45.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1102619401"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1102619401\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1102619401?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-10 22:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1102619401","market":"nz","top_or_hot":-1,"title":"Stock Track | Zimmer Biomet Soars 5.32% Intraday on Q4 Earnings Beat and Strong Hips, Knees Device Demand","media":"Stock Track","content":"<p>Zimmer Biomet's stock surged 5.32% during intraday trading on Tuesday, following the company's release of its fourth-quarter financial results.</p><p>The medical device maker reported quarterly adjusted earnings of $2.42 per share, beating analyst estimates of $2.40. Quarterly sales reached $2.244 billion, also surpassing expectations of $2.231 billion and marking a 10.9% increase year-over-year. The strong performance was driven by robust demand for the company's hips and knees devices, with both segments reporting sales growth.</p><p>Additionally, Zimmer Biomet announced that its board approved a new $1.5 billion stock repurchase authorization, providing further support to shareholder value. The company also issued its 2026 financial guidance, projecting adjusted earnings per share in the range of $8.30 to $8.45.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Zimmer Biomet Soars 5.32% Intraday on Q4 Earnings Beat and Strong Hips, Knees Device Demand</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Zimmer Biomet Soars 5.32% Intraday on Q4 Earnings Beat and Strong Hips, Knees Device Demand\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-10 22:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Zimmer Biomet's stock surged 5.32% during intraday trading on Tuesday, following the company's release of its fourth-quarter financial results.</p><p>The medical device maker reported quarterly adjusted earnings of $2.42 per share, beating analyst estimates of $2.40. Quarterly sales reached $2.244 billion, also surpassing expectations of $2.231 billion and marking a 10.9% increase year-over-year. The strong performance was driven by robust demand for the company's hips and knees devices, with both segments reporting sales growth.</p><p>Additionally, Zimmer Biomet announced that its board approved a new $1.5 billion stock repurchase authorization, providing further support to shareholder value. The company also issued its 2026 financial guidance, projecting adjusted earnings per share in the range of $8.30 to $8.45.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ZBH","symbol_name":"齐默巴奥米特控股","start_time":0,"source_url":"","article_id":"1102619401","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1102619401","pubTimestamp":1770733983,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Zimmer Biomet's stock surged 5.32% during intraday trading on Tuesday, following the company's release of its fourth-quarter financial results.The medical device maker reported quarterly adjusted...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ZBH":"齐默巴奥米特控股"},"translate_title":"个股追踪|Zimmer Biomet盘中飙升5.32%，因Q4盈利超出预期和强劲的髋膝器械需求","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZBH":1},"content_text":"Zimmer Biomet's stock surged 5.32% during intraday trading on Tuesday, following the company's release of its fourth-quarter financial results.The medical device maker reported quarterly adjusted earnings of $2.42 per share, beating analyst estimates of $2.40. Quarterly sales reached $2.244 billion, also surpassing expectations of $2.231 billion and marking a 10.9% increase year-over-year. The strong performance was driven by robust demand for the company's hips and knees devices, with both segments reporting sales growth.Additionally, Zimmer Biomet announced that its board approved a new $1.5 billion stock repurchase authorization, providing further support to shareholder value. The company also issued its 2026 financial guidance, projecting adjusted earnings per share in the range of $8.30 to $8.45.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}